Published in Cancer Weekly, August 16th, 1999
Previous studies examining the effect of interferon (IFN) therapy on the incidence of hepatocellular carcinoma have not sufficiently assessed degree of liver fibrosis, a major risk factor for liver cancer.
In this retrospective study of IFN and hepatocellular carcinoma, H. Yoshidi and colleagues of Japan's University of Tokyo attempted to correct for this oversight by adjusting for risk factors, including the degree of liver fibrosis.
Seven university hospitals and one regional...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.